Physician profile
Amanda E Ford
NPI 1417532292
$7,473.30
in general payments reported to CMS, 2019-2025
42 companies · $2,400 in 2025
The $2,400 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $442 · 2022: $1,482 · 2023: $1,451 · 2024: $1,697 · 2025: $2,400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,548.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,485.20 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,083.62 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $543.73 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $523.50 | 2022-2025 | Rexulti |
| Pfizer INC. | $451.02 | 2021-2025 | |
| Dexcom, INC. | $422.69 | 2021-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $357.17 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Sumitomo Pharma America, INC. | $290.05 | 2023-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $236.22 | 2021-2025 | Xifaxan, Trulance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $226.32 | 2024-2025 | Caplyta |
| Amgen INC. | $206.77 | 2021-2025 | Otezla, Repatha, Otezla |
| Viatris Specialty LLC | $139.24 | 2025 | Yupelri |
| Glaxosmithkline, LLC. | $125.97 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Biohaven Pharmaceuticals, INC. | $124.47 | 2021 | |
| Lundbeck LLC | $119.03 | 2024-2025 | Rexulti |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.